We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-2.4%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.42B
AUM Growth
-$48.5M
Cap. Flow
+$49.9M
Cap. Flow %
3.5%
Top 10 Hldgs %
29.29%
Holding
97
New
3
Increased
35
Reduced
20
Closed
5

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$33.3M
2
PFE icon
Pfizer
PFE
+$22.2M
3
BIIB icon
Biogen
BIIB
+$19.7M
4
APLS
Apellis Pharmaceuticals
APLS
+$14.4M
5
MCK icon
McKesson
MCK
+$14M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$25.6M
2
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$20.4M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$14M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$9.94M
5
PHR icon
Phreesia
PHR
+$9.11M

Sector Composition

Rank Sector Weight
1 Healthcare 96.82%
2 Industrials 1.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$51.5M 3.61%
470,000
-55,000
-10% -$5.71M
UNH icon
2
UnitedHealth
UNH
$376B
$48.8M 3.43%
125,000
– –
ELV icon
3
Elevance Health
ELV
$81.5B
$44.7M 3.14%
120,000
+25,000
+26% +$9.5M
JNJ icon
4
Johnson & Johnson
JNJ
$618B
$43.6M 3.06%
270,000
+195,000
+260% +$33.3M
PFE icon
5
Pfizer
PFE
$143B
$43M 3.02%
1,000,000
+500,000
+100% +$22.2M
BIIB icon
6
Biogen
BIIB
$30B
$42.4M 2.98%
150,000
+60,000
+67% +$19.7M
ABBV icon
7
AbbVie
ABBV
$443B
$38.3M 2.69%
355,000
+35,000
+11% +$4M
JAZZ icon
8
Jazz Pharmaceuticals
JAZZ
$15.9B
$36.5M 2.56%
280,000
+60,000
+27% +$9.07M
TMO icon
9
Thermo Fisher Scientific
TMO
$213B
$34.3M 2.41%
60,000
+10,000
+20% +$5.49M
MDT icon
10
Medtronic
MDT
$109B
$34.2M 2.4%
273,000
– –
CVS icon
11
CVS Health
CVS
$133B
$33.9M 2.38%
400,000
+20,000
+5% +$1.68M
LLY icon
12
Eli Lilly
LLY
$1.02T
$33.5M 2.35%
145,000
+26,200
+22% +$6.47M
VRTX icon
13
Vertex Pharmaceuticals
VRTX
$121B
$29.9M 2.1%
165,000
-50,897
-24% -$9.94M
MCK icon
14
McKesson
MCK
$100B
$29.5M 2.07%
148,000
+70,000
+90% +$14M
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$26.5M 1.86%
150,000
-15,000
-9% -$2.41M
GH icon
16
Guardant Health
GH
$21.7B
$25.6M 1.8%
205,000
+30,000
+17% +$3.56M
CI icon
17
Cigna
CI
$73.7B
$25.4M 1.78%
127,000
-3,500
-3% -$761K
BSX icon
18
Boston Scientific
BSX
$69.5B
$24.7M 1.74%
570,000
+50,000
+10% +$2.21M
ABT icon
19
Abbott
ABT
$183B
$24.3M 1.71%
206,000
-44,000
-18% -$5.4M
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
$22.9M 1.61%
135,000
-22,925
-15% -$3.57M
ABMD
21
DELISTED
Abiomed Inc
ABMD
$22.8M 1.6%
70,000
+5,000
+8% +$1.69M
MRK icon
22
Merck
MRK
$322B
$22.5M 1.58%
300,000
– –
COR icon
23
Cencora
COR
$60.6B
$22.5M 1.58%
188,000
+15,000
+9% +$1.8M
HUM icon
24
Humana
HUM
$43.7B
$22.2M 1.56%
57,000
+2,000
+4% +$849K
GILD icon
25
Gilead Sciences
GILD
$162B
$21M 1.47%
300,000
– –
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2021 Portfolio in Review

As of Q3 2021, Rhenman & Partners Asset Management held 97 positions worth $1.42B, down 3.3% from $1.47B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $49.9M of net new capital in Q3 2021, opening 3 new positions and adding to 35 existing holdings. Its largest new stake was Privia Health: 240,000 shares worth $5.65M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Acceleron Pharma, an estimated $25.6M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2021 buy was Privia Health: 240,000 shares worth $5.65M.
  • Rhenman & Partners Asset Management added most to Johnson & Johnson in Q3 2021, an estimated $33.3M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2021 reduction was Acceleron Pharma, cutting an estimated $25.6M.
  • Rhenman & Partners Asset Management fully exited Inovalon Holdings, Inc. Class A Common Stock in Q3 2021, selling an estimated $20.4M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.42B portfolio in Q3 2021.
  • Rhenman & Partners Asset Management opened 3 new positions and closed 5 in Q3 2021.
  • Rhenman & Partners Asset Management's portfolio value fell 3.3% quarter-over-quarter to $1.42B.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.